2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 365

Monoclonal Gammopathy in Rheumatic Diseases

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 125

Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 212

Mortality and Causes of Death in Patients with Inflammatory Arthritis in Hong Kong over 20 Years

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 654

MRI Lesion Definitions in Axial Spondyloarthritis: A Consensus Reappraisal from the Assessments in Spondyloarthritis International Society

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 609

Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 381

Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 398

Muscle Function and Health-Related Quality of Life in Patients with Polymyositis and Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster – ARHP

9:00AM-11:00AM: Abstract Number: 399

Musculoskeletal Comorbidities after Total Knee Replacement for Osteoarthritis

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 357

Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia

Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 131

Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 383

Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 397

Myositis-Specific Autoantibodies and Their Clinical Associations

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 382

Nailfold Capillary Changes in the Adult Newly Onset-Dermatomyositis: A Prospective Cohort Study

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 374

Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?

Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

9:00AM-11:00AM: Abstract Number: 182

Needs Assessment of a Structured Program for Fellows As Teachers: Rheumatology Program Directors’ Perspective

Education Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.